133 related articles for article (PubMed ID: 3936564)
1. Mitomycin C in superficial bladder cancer: 24-month follow-up.
Somerville JJ; Newling DW; Richards B; Robinson MR; Smith PH
Br J Urol; 1985 Dec; 57(6):686-9. PubMed ID: 3936564
[TBL] [Abstract][Full Text] [Related]
2. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
Soloway MS
J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
[TBL] [Abstract][Full Text] [Related]
3. Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours.
Hetherington JW; Newling DW; Robinson MR; Smith PH; Adib RS; Whelan P
Br J Urol; 1987 Mar; 59(3):239-41. PubMed ID: 3105631
[TBL] [Abstract][Full Text] [Related]
4. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
5. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Zincke H; Benson RC; Hilton JF; Taylor WF
J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
[TBL] [Abstract][Full Text] [Related]
6. Intravesical chemotherapy for carcinoma in situ of the urinary bladder: 5 years later.
Jakse G
Eur Urol; 1984; 10(5):289-93. PubMed ID: 6440791
[TBL] [Abstract][Full Text] [Related]
7. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
8. The effect of mitomycin C on superficial bladder cancer.
Soloway MS; Murphy WM; DeFuria MD; Crooke S; Finebaum P
J Urol; 1981 May; 125(5):646-8. PubMed ID: 6785454
[TBL] [Abstract][Full Text] [Related]
9. Topical mitomycin C therapy for carcinoma in situ of the bladder: a followup.
Stricker PD; Grant AB; Hosken BM; Taylor JS
J Urol; 1990 Jan; 143(1):34-5; discussion 35-6. PubMed ID: 2104637
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH
Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263
[TBL] [Abstract][Full Text] [Related]
11. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
Mobley WC; Loening SA; Narayana AS; Culp DA
Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
[TBL] [Abstract][Full Text] [Related]
12. Long-term observation after intravesical metaphylaxis with mitomycin C in patients with superficial bladder tumors.
Maier U; Höbarth K
Urology; 1991 May; 37(5):481-2. PubMed ID: 1902606
[TBL] [Abstract][Full Text] [Related]
13. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
14. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
Giesbers AA; Van Helsdingen PJ; Kramer AE
Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
[TBL] [Abstract][Full Text] [Related]
15. [Mitomycin C in the topical treatment of superficial neoplasms of the bladder].
Milani C; Bassi PF; Meneghini A; Giunta A; Tejerizo JC; dal Bianco M; Zattoni F; Garbeglio A
Arch Esp Urol; 1989 Oct; 42(8):761-7. PubMed ID: 2515812
[TBL] [Abstract][Full Text] [Related]
16. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
Droller MJ; Walsh PC
J Urol; 1985 Dec; 134(6):1115-7. PubMed ID: 3932686
[TBL] [Abstract][Full Text] [Related]
17. Histological grading of carcinoma in situ of the bladder: its clinical significance in patients who underwent intravesical mitomycin C and doxorubicin sequential therapy.
Sekine H; Fukui I; Yamada T; Yamada T; Kojima S; Ohshima H
J Urol; 1996 Jan; 155(1):94-8; discussion 98-9. PubMed ID: 7490908
[TBL] [Abstract][Full Text] [Related]
18. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival.
Huland H; Otto U; Droese M; Klöppel G
J Urol; 1984 Jul; 132(1):27-9. PubMed ID: 6427483
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma in situ associated with superficial bladder tumor.
Solsona E; Iborra I; Ricós JV; Monrós JL; Dumont R; Casanova J; Calabuig C
Eur Urol; 1991; 19(2):93-6. PubMed ID: 1902418
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer.
Cant JD; Murphy WM; Soloway MS
Cancer; 1986 Jun; 57(11):2119-22. PubMed ID: 3084057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
